You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMetyrosine
Accession NumberDB00765  (APRD01112)
TypeSmall Molecule
GroupsApproved
DescriptionAn inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. (Martindale, The Extra Pharmacopoeia, 30th ed)
Structure
Thumb
Synonyms
(-)-alpha-Methyl-L-tyrosine
(S)-alpha-Methyltyrosine
alpha-Methyl-L-P-tyrosine
alpha-Methyl-P-tyrosine
alpha-Methyl-para-tyrosine
alpha-Methyltyrosine
L-alpha-Methyltyrosine
Methyltyrosine
Metirosin
Metirosina
Métirosine
Metirosine
Metirosinum
Metyrosine
External Identifiers
  • 357 O
  • L 588
  • L 588357-0
  • MK 781
  • α-MPT
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DemserCapsule250 mg/1OralAton Pharma, Inc.1979-10-03Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIDOQ0J0TPF7
CAS number672-87-7
WeightAverage: 195.2151
Monoisotopic: 195.089543287
Chemical FormulaC10H13NO3
InChI KeyNHTGHBARYWONDQ-JTQLQIEISA-N
InChI
InChI=1S/C10H13NO3/c1-10(11,9(13)14)6-7-2-4-8(12)5-3-7/h2-5,12H,6,11H2,1H3,(H,13,14)/t10-/m0/s1
IUPAC Name
(2S)-2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid
SMILES
C[C@](N)(CC1=CC=C(O)C=C1)C(O)=O
Pharmacology
IndicationFor use in the treatment of patients with pheochromocytoma, for preoperative preparation of patients for surgery, management of patients when surgery is contraindicated, and chronic treatment of patients with malignant pheochromocytoma.
Structured Indications
PharmacodynamicsIn patients with pheochromocytoma, who produce excessive amounts of norepinephrine and epinephrine, administration of one to four grams of metyrosine per day has reduced catecholamine biosynthesis from about 35 to 80 percent as measured by the total excretion of catecholamines and their metabolites (metanephrine and vanillylmandelic acid). The maximum biochemical effect usually occurs within two to three days, and the urinary concentration of catecholamines and their metabolites usually returns to pretreatment levels within three to four days after metyrosine is discontinued. Most patients with pheochromocytoma treated with metyrosine experience decreased frequency and severity of hypertensive attacks with their associated headache, nausea, sweating, and tachycardia. In patients who respond, blood pressure decreases progressively during the first two days of therapy with metyrosine; after withdrawal, blood pressure usually increases gradually to pretreatment values within two to three days.
Mechanism of actionMetyrosine inhibits tyrosine hydroxylase, which catalyzes the first transformation in catecholamine biosynthesis, i.e., the conversion of tyrosine to dihydroxyphenylalanine (DOPA). Because the first step is also the rate-limiting step, blockade of tyrosine hydroxylase activity results in decreased endogenous levels of catecholamines and their synthesis. This consequently, depletes the levels of the catecholamines dopamine, adrenaline and noradrenaline in the body,usually measured as decreased urinary excretion of catecholamines and their metabolites. One main end result of the catecholamine depletion is a decrease in blood presure.
TargetKindPharmacological actionActionsOrganismUniProt ID
Tyrosine 3-monooxygenaseProteinyes
binder
HumanP07101 details
Related Articles
AbsorptionWell absorbed from the gastrointestinal tract.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Little biotransformation, with catechol metabolites accounting for less than 1% of the administered dose.

Route of eliminationBecause the first step is also the rate-limiting step, blockade of tyrosine hydroxylase activity results in decreased endogenous levels of catecholamines, usually measured as decreased urinary excretion of catecholamines and their metabolites.
Half life3.4 to 3.7 hours
ClearanceNot Available
ToxicitySigns of metyrosine overdosage include those central nervous system effects observed in some patients even at low dosages. At doses exceeding 2000 mg/day, some degree of sedation or feeling of fatigue may persist. Doses of 2000-4000 mg/day can result in anxiety or agitated depression, neuromuscular effects (including fine tremor of the hands, gross tremor of the trunk, tightening of the jaw with trismus), diarrhea, and decreased salivation with dry mouth. The acute toxicity of metyrosine was 442 mg/kg and 752 mg/kg in the female mouse and rat respectively.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 Tetrafluoroethane1,1,1,2 Tetrafluoroethane may increase the sedative activities of Metyrosine.Investigational
7-Nitroindazole7-Nitroindazole may increase the sedative activities of Metyrosine.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Metyrosine.Experimental
AcebutololAcebutolol may increase the hypotensive activities of Metyrosine.Approved
AcepromazineAcepromazine may increase the sedative activities of Metyrosine.Approved, Vet Approved
AceprometazineAceprometazine may increase the sedative activities of Metyrosine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Acetophenazine.Approved
adipiplonadipiplon may increase the sedative activities of Metyrosine.Investigational
AgomelatineAgomelatine may increase the sedative activities of Metyrosine.Approved, Investigational
AlfaxaloneAlfaxalone may increase the sedative activities of Metyrosine.Vet Approved
AlfentanilAlfentanil may increase the sedative activities of Metyrosine.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Metyrosine.Approved, Investigational
AliskirenAliskiren may increase the hypotensive activities of Metyrosine.Approved, Investigational
AlphacetylmethadolAlphacetylmethadol may increase the sedative activities of Metyrosine.Experimental, Illicit
AlprazolamAlprazolam may increase the sedative activities of Metyrosine.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Metyrosine.Approved, Withdrawn
AmbrisentanAmbrisentan may increase the hypotensive activities of Metyrosine.Approved, Investigational
AmifostineMetyrosine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmineptineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Amineptine.Illicit, Withdrawn
AmisulprideAmisulpride may increase the sedative activities of Metyrosine.Approved, Investigational
AmitriptylineAmitriptyline may increase the sedative activities of Metyrosine.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Metyrosine.Approved
AmobarbitalAmobarbital may increase the sedative activities of Metyrosine.Approved, Illicit
AmoxapineAmoxapine may increase the sedative activities of Metyrosine.Approved
AmperozideAmperozide may increase the sedative activities of Metyrosine.Experimental
AripiprazoleAripiprazole may increase the sedative activities of Metyrosine.Approved, Investigational
ArticaineArticaine may increase the sedative activities of Metyrosine.Approved
AsenapineAsenapine may increase the sedative activities of Metyrosine.Approved
AtenololAtenolol may increase the hypotensive activities of Metyrosine.Approved
AzaperoneAzaperone may increase the sedative activities of Metyrosine.Vet Approved
AzelastineAzelastine may increase the sedative activities of Metyrosine.Approved
BaclofenBaclofen may increase the sedative activities of Metyrosine.Approved
BarbitalBarbital may increase the sedative activities of Metyrosine.Illicit
BenazeprilBenazepril may increase the hypotensive activities of Metyrosine.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Metyrosine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Metyrosine.Withdrawn
BenperidolBenperidol may increase the sedative activities of Metyrosine.Investigational
BenzocaineBenzocaine may increase the sedative activities of Metyrosine.Approved
Benzyl alcoholBenzyl alcohol may increase the sedative activities of Metyrosine.Approved
BepridilBepridil may increase the hypotensive activities of Metyrosine.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Metyrosine.Approved
BethanidineBethanidine may increase the hypotensive activities of Metyrosine.Approved
BifeprunoxThe risk or severity of adverse effects can be increased when Metyrosine is combined with Bifeprunox.Investigational
BimatoprostBimatoprost may increase the hypotensive activities of Metyrosine.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Metyrosine.Approved
BosentanBosentan may increase the hypotensive activities of Metyrosine.Approved, Investigational
BretyliumBretylium may increase the hypotensive activities of Metyrosine.Approved
BrexpiprazoleBrexpiprazole may increase the sedative activities of Metyrosine.Approved
BrimonidineBrimonidine may increase the sedative activities of Metyrosine.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Metyrosine.Approved
BromazepamBromazepam may increase the sedative activities of Metyrosine.Approved, Illicit
BromperidolThe risk or severity of adverse effects can be increased when Metyrosine is combined with Bromperidol.Investigational
BrompheniramineBrompheniramine may increase the sedative activities of Metyrosine.Approved
BrotizolamBrotizolam may increase the sedative activities of Metyrosine.Approved, Withdrawn
BupivacaineBupivacaine may increase the sedative activities of Metyrosine.Approved, Investigational
BupranololBupranolol may increase the hypotensive activities of Metyrosine.Approved
BuprenorphineBuprenorphine may increase the sedative activities of Metyrosine.Approved, Illicit, Investigational, Vet Approved
BuspironeBuspirone may increase the sedative activities of Metyrosine.Approved, Investigational
ButabarbitalButabarbital may increase the sedative activities of Metyrosine.Approved, Illicit
ButacaineButacaine may increase the sedative activities of Metyrosine.Vet Approved
ButalbitalButalbital may increase the sedative activities of Metyrosine.Approved, Illicit
ButambenButamben may increase the sedative activities of Metyrosine.Approved
ButethalButethal may increase the sedative activities of Metyrosine.Approved, Illicit
ButorphanolButorphanol may increase the sedative activities of Metyrosine.Approved, Illicit, Vet Approved
CandesartanCandesartan may increase the hypotensive activities of Metyrosine.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Metyrosine.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Metyrosine.Approved
CarbamazepineCarbamazepine may increase the sedative activities of Metyrosine.Approved, Investigational
CarbinoxamineCarbinoxamine may increase the sedative activities of Metyrosine.Approved
CarfentanilCarfentanil may increase the sedative activities of Metyrosine.Illicit, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Cariprazine.Approved
CarisoprodolCarisoprodol may increase the sedative activities of Metyrosine.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Metyrosine.Withdrawn
CarteololCarteolol may increase the hypotensive activities of Metyrosine.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Metyrosine.Approved, Investigational
CeliprololCeliprolol may increase the hypotensive activities of Metyrosine.Approved, Investigational
CetirizineCetirizine may increase the sedative activities of Metyrosine.Approved
Chloral hydrateChloral hydrate may increase the sedative activities of Metyrosine.Approved, Illicit, Vet Approved
ChlordiazepoxideChlordiazepoxide may increase the sedative activities of Metyrosine.Approved, Illicit
ChlormezanoneChlormezanone may increase the sedative activities of Metyrosine.Approved, Withdrawn
ChloroprocaineChloroprocaine may increase the sedative activities of Metyrosine.Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Metyrosine.Approved, Vet Approved
ChlorphenamineChlorphenamine may increase the sedative activities of Metyrosine.Approved
ChlorpromazineChlorpromazine may increase the sedative activities of Metyrosine.Approved, Vet Approved
ChlorprothixeneChlorprothixene may increase the sedative activities of Metyrosine.Approved, Withdrawn
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Metyrosine.Approved
ChlorzoxazoneChlorzoxazone may increase the sedative activities of Metyrosine.Approved
CilazaprilCilazapril may increase the hypotensive activities of Metyrosine.Approved
CinchocaineCinchocaine may increase the sedative activities of Metyrosine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Metyrosine is combined with Citalopram.Approved
ClemastineClemastine may increase the sedative activities of Metyrosine.Approved
ClidiniumClidinium may increase the sedative activities of Metyrosine.Approved
ClobazamClobazam may increase the sedative activities of Metyrosine.Approved, Illicit
clomethiazoleclomethiazole may increase the sedative activities of Metyrosine.Investigational
ClomipramineClomipramine may increase the sedative activities of Metyrosine.Approved, Vet Approved
ClonazepamClonazepam may increase the sedative activities of Metyrosine.Approved, Illicit
ClonidineClonidine may increase the sedative activities of Metyrosine.Approved
ClorazepateClorazepate may increase the sedative activities of Metyrosine.Approved, Illicit
ClozapineClozapine may increase the sedative activities of Metyrosine.Approved
CocaineCocaine may increase the sedative activities of Metyrosine.Approved, Illicit
CodeineCodeine may increase the sedative activities of Metyrosine.Approved, Illicit
CryptenamineCryptenamine may increase the hypotensive activities of Metyrosine.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Cyamemazine.Approved
CyclizineCyclizine may increase the sedative activities of Metyrosine.Approved
CyclobenzaprineCyclobenzaprine may increase the sedative activities of Metyrosine.Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Metyrosine.Approved
CyproheptadineCyproheptadine may increase the sedative activities of Metyrosine.Approved
DantroleneDantrolene may increase the sedative activities of Metyrosine.Approved
DapiprazoleDapiprazole may increase the sedative activities of Metyrosine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Dapoxetine.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Metyrosine.Approved
deramciclanederamciclane may increase the sedative activities of Metyrosine.Investigational
DeserpidineDeserpidine may increase the hypotensive activities of Metyrosine.Approved
DesfluraneDesflurane may increase the sedative activities of Metyrosine.Approved
DesipramineDesipramine may increase the sedative activities of Metyrosine.Approved
DesloratadineDesloratadine may increase the sedative activities of Metyrosine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Desvenlafaxine.Approved
DetomidineDetomidine may increase the sedative activities of Metyrosine.Vet Approved
DexbrompheniramineDexbrompheniramine may increase the sedative activities of Metyrosine.Approved
DexmedetomidineDexmedetomidine may increase the sedative activities of Metyrosine.Approved, Vet Approved
DextromoramideDextromoramide may increase the sedative activities of Metyrosine.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the sedative activities of Metyrosine.Approved, Illicit, Withdrawn
DezocineDezocine may increase the sedative activities of Metyrosine.Approved
DiazepamDiazepam may increase the sedative activities of Metyrosine.Approved, Illicit, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Metyrosine.Approved
DifenoxinDifenoxin may increase the sedative activities of Metyrosine.Approved, Illicit
DihydralazineMetyrosine may increase the hypotensive activities of Dihydralazine.Investigational
DihydrocodeineDihydrocodeine may increase the sedative activities of Metyrosine.Approved, Illicit
DihydroetorphineDihydroetorphine may increase the sedative activities of Metyrosine.Experimental, Illicit
DihydromorphineDihydromorphine may increase the sedative activities of Metyrosine.Experimental, Illicit
DiltiazemDiltiazem may increase the hypotensive activities of Metyrosine.Approved
DimenhydrinateDimenhydrinate may increase the sedative activities of Metyrosine.Approved
DiphenhydramineDiphenhydramine may increase the sedative activities of Metyrosine.Approved
DiphenoxylateDiphenoxylate may increase the sedative activities of Metyrosine.Approved, Illicit
DoramectinDoramectin may increase the sedative activities of Metyrosine.Vet Approved
DorzolamideDorzolamide may increase the hypotensive activities of Metyrosine.Approved
DosulepinThe risk or severity of adverse effects can be increased when Metyrosine is combined with Dosulepin.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Metyrosine.Approved
DoxepinDoxepin may increase the sedative activities of Metyrosine.Approved
DoxylamineDoxylamine may increase the sedative activities of Metyrosine.Approved, Vet Approved
DPDPEDPDPE may increase the sedative activities of Metyrosine.Investigational
DroperidolThe risk or severity of adverse effects can be increased when Metyrosine is combined with Droperidol.Approved, Vet Approved
DrotebanolDrotebanol may increase the sedative activities of Metyrosine.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Duloxetine.Approved
DyclonineDyclonine may increase the sedative activities of Metyrosine.Approved
EcgonineEcgonine may increase the sedative activities of Metyrosine.Experimental, Illicit
ECGONINE METHYL ESTERECGONINE METHYL ESTER may increase the sedative activities of Metyrosine.Experimental
EcopipamEcopipam may increase the sedative activities of Metyrosine.Investigational
EfavirenzEfavirenz may increase the sedative activities of Metyrosine.Approved, Investigational
EfonidipineEfonidipine may increase the hypotensive activities of Metyrosine.Approved
EnalaprilEnalapril may increase the hypotensive activities of Metyrosine.Approved, Vet Approved
EnalaprilatEnalaprilat may increase the hypotensive activities of Metyrosine.Approved
EnfluraneEnflurane may increase the sedative activities of Metyrosine.Approved, Vet Approved
EntacaponeEntacapone may increase the sedative activities of Metyrosine.Approved, Investigational
EpoprostenolEpoprostenol may increase the hypotensive activities of Metyrosine.Approved
EprosartanEprosartan may increase the hypotensive activities of Metyrosine.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Metyrosine is combined with Escitalopram.Approved, Investigational
EsmirtazapineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Esmirtazapine.Investigational
EstazolamEstazolam may increase the sedative activities of Metyrosine.Approved, Illicit
EszopicloneEszopiclone may increase the sedative activities of Metyrosine.Approved
EthanolEthanol may increase the sedative activities of Metyrosine.Approved
EthchlorvynolEthchlorvynol may increase the sedative activities of Metyrosine.Approved, Illicit, Withdrawn
EthosuximideEthosuximide may increase the sedative activities of Metyrosine.Approved
EthotoinEthotoin may increase the sedative activities of Metyrosine.Approved
Ethyl carbamateEthyl carbamate may increase the sedative activities of Metyrosine.Withdrawn
Ethyl loflazepateEthyl loflazepate may increase the sedative activities of Metyrosine.Approved, Illicit
EthylmorphineEthylmorphine may increase the sedative activities of Metyrosine.Approved, Illicit
EtidocaineEtidocaine may increase the sedative activities of Metyrosine.Approved
EtifoxineEtifoxine may increase the sedative activities of Metyrosine.Withdrawn
EtizolamEtizolam may increase the sedative activities of Metyrosine.Approved
EtomidateEtomidate may increase the sedative activities of Metyrosine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Metyrosine is combined with Etoperidone.Approved
EtorphineEtorphine may increase the sedative activities of Metyrosine.Illicit, Vet Approved
EzogabineEzogabine may increase the sedative activities of Metyrosine.Approved
FelbamateFelbamate may increase the sedative activities of Metyrosine.Approved
FelodipineFelodipine may increase the hypotensive activities of Metyrosine.Approved, Investigational
FencamfamineFencamfamine may increase the sedative activities of Metyrosine.Approved, Illicit, Withdrawn
FenoldopamFenoldopam may increase the hypotensive activities of Metyrosine.Approved
FentanylFentanyl may increase the sedative activities of Metyrosine.Approved, Illicit, Investigational, Vet Approved
FexofenadineFexofenadine may increase the sedative activities of Metyrosine.Approved
FlibanserinFlibanserin may increase the sedative activities of Metyrosine.Approved
FludiazepamFludiazepam may increase the sedative activities of Metyrosine.Approved, Illicit
FlunarizineFlunarizine may increase the sedative activities of Metyrosine.Approved
FlunitrazepamFlunitrazepam may increase the sedative activities of Metyrosine.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolFlupentixol may increase the sedative activities of Metyrosine.Approved, Withdrawn
FluphenazineFluphenazine may increase the sedative activities of Metyrosine.Approved
FlurazepamFlurazepam may increase the sedative activities of Metyrosine.Approved, Illicit
FluspirileneFluspirilene may increase the sedative activities of Metyrosine.Approved
Fluticasone PropionateFluticasone Propionate may increase the sedative activities of Metyrosine.Approved
FluvoxamineFluvoxamine may increase the sedative activities of Metyrosine.Approved, Investigational
FosinoprilFosinopril may increase the hypotensive activities of Metyrosine.Approved
FosphenytoinFosphenytoin may increase the sedative activities of Metyrosine.Approved
FospropofolFospropofol may increase the sedative activities of Metyrosine.Approved, Illicit
FurazolidoneFurazolidone may increase the hypotensive activities of Metyrosine.Approved, Vet Approved
GabapentinGabapentin may increase the sedative activities of Metyrosine.Approved, Investigational
gabapentin enacarbilgabapentin enacarbil may increase the sedative activities of Metyrosine.Approved
Gamma Hydroxybutyric AcidGamma Hydroxybutyric Acid may increase the sedative activities of Metyrosine.Approved, Illicit
GepironeGepirone may increase the sedative activities of Metyrosine.Investigational
GlutethimideGlutethimide may increase the sedative activities of Metyrosine.Approved, Illicit
GuanabenzGuanabenz may increase the hypotensive activities of Metyrosine.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Metyrosine.Approved
GuanethidineGuanethidine may increase the hypotensive activities of Metyrosine.Approved
GuanfacineGuanfacine may increase the sedative activities of Metyrosine.Approved, Investigational
HalazepamHalazepam may increase the sedative activities of Metyrosine.Approved, Illicit, Withdrawn
HaloperidolHaloperidol may increase the sedative activities of Metyrosine.Approved
HalothaneHalothane may increase the sedative activities of Metyrosine.Approved, Vet Approved
HeroinHeroin may increase the sedative activities of Metyrosine.Approved, Illicit
HexamethoniumHexamethonium may increase the hypotensive activities of Metyrosine.Experimental
HexobarbitalHexobarbital may increase the sedative activities of Metyrosine.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Metyrosine.Approved
HydralazineHydralazine may increase the hypotensive activities of Metyrosine.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Metyrosine.Approved, Vet Approved
HydrocodoneHydrocodone may increase the sedative activities of Metyrosine.Approved, Illicit
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Metyrosine.Approved
HydromorphoneHydromorphone may increase the sedative activities of Metyrosine.Approved, Illicit
HydroxyzineHydroxyzine may increase the sedative activities of Metyrosine.Approved
IloperidoneIloperidone may increase the sedative activities of Metyrosine.Approved
IloprostIloprost may increase the hypotensive activities of Metyrosine.Approved, Investigational
ImidaprilMetyrosine may increase the hypotensive activities of Imidapril.Investigational
ImipramineImipramine may increase the sedative activities of Metyrosine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the hypotensive activities of Metyrosine.Approved
IndenololIndenolol may increase the hypotensive activities of Metyrosine.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Metyrosine.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Metyrosine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Metyrosine.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Metyrosine.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Metyrosine.Approved
IsofluraneIsoflurane may increase the sedative activities of Metyrosine.Approved, Vet Approved
IsradipineIsradipine may increase the hypotensive activities of Metyrosine.Approved
KetamineKetamine may increase the sedative activities of Metyrosine.Approved, Vet Approved
KetanserinMetyrosine may increase the hypotensive activities of Ketanserin.Investigational
KetazolamKetazolam may increase the sedative activities of Metyrosine.Approved
KetobemidoneKetobemidone may increase the sedative activities of Metyrosine.Approved
LabetalolLabetalol may increase the hypotensive activities of Metyrosine.Approved
LacidipineLacidipine may increase the hypotensive activities of Metyrosine.Approved
LamotrigineLamotrigine may increase the sedative activities of Metyrosine.Approved, Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Metyrosine.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Metyrosine.Approved, Investigational
LevetiracetamLevetiracetam may increase the sedative activities of Metyrosine.Approved, Investigational
LevobupivacaineLevobupivacaine may increase the sedative activities of Metyrosine.Approved
LevocabastineLevocabastine may increase the sedative activities of Metyrosine.Approved
LevocetirizineLevocetirizine may increase the sedative activities of Metyrosine.Approved
LevodopaLevodopa may increase the sedative activities of Metyrosine.Approved
Levomethadyl AcetateLevomethadyl Acetate may increase the sedative activities of Metyrosine.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Metyrosine is combined with Levomilnacipran.Approved
LevorphanolLevorphanol may increase the sedative activities of Metyrosine.Approved
LidocaineLidocaine may increase the sedative activities of Metyrosine.Approved, Vet Approved
LisinoprilLisinopril may increase the hypotensive activities of Metyrosine.Approved, Investigational
LithiumLithium may increase the sedative activities of Metyrosine.Approved
LofentanilLofentanil may increase the sedative activities of Metyrosine.Illicit
LofexidineLofexidine may increase the hypotensive activities of Metyrosine.Approved, Investigational
LoratadineLoratadine may increase the sedative activities of Metyrosine.Approved
LorazepamLorazepam may increase the sedative activities of Metyrosine.Approved
LosartanLosartan may increase the hypotensive activities of Metyrosine.Approved
LoxapineLoxapine may increase the sedative activities of Metyrosine.Approved
Lu AA21004Lu AA21004 may increase the sedative activities of Metyrosine.Investigational
LurasidoneLurasidone may increase the sedative activities of Metyrosine.Approved
MacitentanMacitentan may increase the hypotensive activities of Metyrosine.Approved
Magnesium SulfateMagnesium Sulfate may increase the sedative activities of Metyrosine.Approved, Vet Approved
ManidipineManidipine may increase the hypotensive activities of Metyrosine.Approved
MaprotilineMaprotiline may increase the sedative activities of Metyrosine.Approved
MebanazineMebanazine may increase the hypotensive activities of Metyrosine.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Metyrosine.Approved
MeclizineMeclizine may increase the sedative activities of Metyrosine.Approved
MedetomidineMedetomidine may increase the sedative activities of Metyrosine.Vet Approved
MelatoninMelatonin may increase the sedative activities of Metyrosine.Approved, Nutraceutical, Vet Approved
MelperoneMelperone may increase the sedative activities of Metyrosine.Approved
MepivacaineMepivacaine may increase the sedative activities of Metyrosine.Approved, Vet Approved
MeprobamateMeprobamate may increase the sedative activities of Metyrosine.Approved, Illicit
MesoridazineMesoridazine may increase the sedative activities of Metyrosine.Approved
MetaxaloneMetaxalone may increase the sedative activities of Metyrosine.Approved
MethadoneMethadone may increase the sedative activities of Metyrosine.Approved
Methadyl AcetateMethadyl Acetate may increase the sedative activities of Metyrosine.Approved, Illicit
MethapyrileneMethapyrilene may increase the sedative activities of Metyrosine.Withdrawn
MethaqualoneMethaqualone may increase the sedative activities of Metyrosine.Illicit, Withdrawn
MethocarbamolMethocarbamol may increase the sedative activities of Metyrosine.Approved, Vet Approved
MethohexitalMethohexital may increase the sedative activities of Metyrosine.Approved
MethotrimeprazineMethotrimeprazine may increase the sedative activities of Metyrosine.Approved
MethoxyfluraneMethoxyflurane may increase the sedative activities of Metyrosine.Approved, Vet Approved
MethsuximideMethsuximide may increase the sedative activities of Metyrosine.Approved
MethyldopaMethyldopa may increase the hypotensive activities of Metyrosine.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Metyrosine.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Metyrosine.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the sedative activities of Metyrosine.Approved
MetipranololMetipranolol may increase the hypotensive activities of Metyrosine.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metyrosine is combined with Metoclopramide.Approved, Investigational
MetolazoneMetolazone may increase the hypotensive activities of Metyrosine.Approved
MetoprololMetoprolol may increase the hypotensive activities of Metyrosine.Approved, Investigational
MibefradilMibefradil may increase the hypotensive activities of Metyrosine.Withdrawn
MidazolamMidazolam may increase the sedative activities of Metyrosine.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Metyrosine is combined with Milnacipran.Approved
MinaprineMinaprine may increase the hypotensive activities of Metyrosine.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Metyrosine.Approved
MirtazapineMirtazapine may increase the sedative activities of Metyrosine.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Metyrosine.Approved
MoexiprilMoexipril may increase the hypotensive activities of Metyrosine.Approved
MolindoneMolindone may increase the sedative activities of Metyrosine.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Metyrosine.Approved
MorphineMorphine may increase the sedative activities of Metyrosine.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Metyrosine.Approved
NabiloneNabilone may increase the sedative activities of Metyrosine.Approved, Investigational
NadololNadolol may increase the hypotensive activities of Metyrosine.Approved
NaftopidilMetyrosine may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineNalbuphine may increase the sedative activities of Metyrosine.Approved
NebivololNebivolol may increase the hypotensive activities of Metyrosine.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Metyrosine is combined with Nefazodone.Approved, Withdrawn
NialamideNialamide may increase the hypotensive activities of Metyrosine.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Metyrosine.Approved
NicorandilNicorandil may increase the hypotensive activities of Metyrosine.Approved
NiguldipineNiguldipine may increase the hypotensive activities of Metyrosine.Experimental
NilvadipineNilvadipine may increase the hypotensive activities of Metyrosine.Approved
NimodipineNimodipine may increase the hypotensive activities of Metyrosine.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Metyrosine.Approved
NitrazepamNitrazepam may increase the sedative activities of Metyrosine.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Metyrosine.Approved
NitroprussideNitroprusside may increase the hypotensive activities of Metyrosine.Approved
Nitrous oxideNitrous oxide may increase the sedative activities of Metyrosine.Approved, Vet Approved
NormethadoneNormethadone may increase the sedative activities of Metyrosine.Approved, Illicit
NortriptylineNortriptyline may increase the sedative activities of Metyrosine.Approved
ObinutuzumabMetyrosine may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Metyrosine.Withdrawn
OlanzapineOlanzapine may increase the sedative activities of Metyrosine.Approved, Investigational
OlmesartanOlmesartan may increase the hypotensive activities of Metyrosine.Approved, Investigational
OlopatadineOlopatadine may increase the sedative activities of Metyrosine.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Metyrosine.Investigational
OndansetronOndansetron may increase the sedative activities of Metyrosine.Approved
OpipramolThe risk or severity of adverse effects can be increased when Metyrosine is combined with Opipramol.Investigational
OpiumOpium may increase the sedative activities of Metyrosine.Approved, Illicit
OrphenadrineOrphenadrine may increase the sedative activities of Metyrosine.Approved
OsanetantOsanetant may increase the sedative activities of Metyrosine.Investigational
OxazepamOxazepam may increase the sedative activities of Metyrosine.Approved
OxetacaineOxetacaine may increase the sedative activities of Metyrosine.Investigational
OxprenololOxprenolol may increase the sedative activities of Metyrosine.Approved
OxybuprocaineOxybuprocaine may increase the sedative activities of Metyrosine.Approved
OxycodoneOxycodone may increase the sedative activities of Metyrosine.Approved, Illicit, Investigational
OxymorphoneOxymorphone may increase the sedative activities of Metyrosine.Approved, Investigational, Vet Approved
PaliperidonePaliperidone may increase the sedative activities of Metyrosine.Approved
ParaldehydeParaldehyde may increase the sedative activities of Metyrosine.Approved
PargylinePargyline may increase the hypotensive activities of Metyrosine.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Paroxetine.Approved, Investigational
PenbutololPenbutolol may increase the hypotensive activities of Metyrosine.Approved, Investigational
PentazocinePentazocine may increase the sedative activities of Metyrosine.Approved, Vet Approved
PentobarbitalPentobarbital may increase the sedative activities of Metyrosine.Approved, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Metyrosine.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Metyrosine.Approved, Investigational
PerampanelPerampanel may increase the sedative activities of Metyrosine.Approved
PerazinePerazine may increase the sedative activities of Metyrosine.Investigational
PerindoprilPerindopril may increase the hypotensive activities of Metyrosine.Approved
PerospironePerospirone may increase the sedative activities of Metyrosine.Approved
PerphenazinePerphenazine may increase the sedative activities of Metyrosine.Approved
PethidinePethidine may increase the sedative activities of Metyrosine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Metyrosine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Metyrosine.Withdrawn
PhenobarbitalPhenobarbital may increase the sedative activities of Metyrosine.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Metyrosine.Approved
PhenoxyethanolPhenoxyethanol may increase the sedative activities of Metyrosine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Metyrosine.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Metyrosine.Approved
PhenytoinPhenytoin may increase the sedative activities of Metyrosine.Approved, Vet Approved
PimozidePimozide may increase the sedative activities of Metyrosine.Approved
PinacidilPinacidil may increase the hypotensive activities of Metyrosine.Withdrawn
PindololPindolol may increase the hypotensive activities of Metyrosine.Approved
PipamperonePipamperone may increase the sedative activities of Metyrosine.Approved
PipotiazinePipotiazine may increase the sedative activities of Metyrosine.Approved
PiritramidePiritramide may increase the sedative activities of Metyrosine.Investigational
PirlindolePirlindole may increase the hypotensive activities of Metyrosine.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Metyrosine.Withdrawn
PizotifenPizotifen may increase the sedative activities of Metyrosine.Approved
PolythiazidePolythiazide may increase the hypotensive activities of Metyrosine.Approved
PomalidomidePomalidomide may increase the sedative activities of Metyrosine.Approved
PramocainePramocaine may increase the sedative activities of Metyrosine.Approved
PrazepamPrazepam may increase the sedative activities of Metyrosine.Approved, Illicit
PrazosinPrazosin may increase the hypotensive activities of Metyrosine.Approved
PregabalinPregabalin may increase the sedative activities of Metyrosine.Approved, Illicit, Investigational
PregnanolonePregnanolone may increase the sedative activities of Metyrosine.Investigational
PrilocainePrilocaine may increase the sedative activities of Metyrosine.Approved
PrimidonePrimidone may increase the sedative activities of Metyrosine.Approved, Vet Approved
ProcaineProcaine may increase the sedative activities of Metyrosine.Approved, Investigational, Vet Approved
ProchlorperazineProchlorperazine may increase the sedative activities of Metyrosine.Approved, Vet Approved
PromazinePromazine may increase the sedative activities of Metyrosine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Promethazine.Approved
ProparacaineProparacaine may increase the sedative activities of Metyrosine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Propericiazine.Approved
PropofolPropofol may increase the sedative activities of Metyrosine.Approved, Investigational, Vet Approved
PropoxycainePropoxycaine may increase the sedative activities of Metyrosine.Approved
PropranololPropranolol may increase the hypotensive activities of Metyrosine.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Metyrosine is combined with Prothipendyl.Investigational
ProtriptylineProtriptyline may increase the sedative activities of Metyrosine.Approved
PSD502PSD502 may increase the sedative activities of Metyrosine.Investigational
QuazepamQuazepam may increase the sedative activities of Metyrosine.Approved, Illicit
QuetiapineQuetiapine may increase the sedative activities of Metyrosine.Approved
QuinaprilQuinapril may increase the hypotensive activities of Metyrosine.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Metyrosine.Approved
RacloprideRaclopride may increase the sedative activities of Metyrosine.Investigational
RamelteonRamelteon may increase the sedative activities of Metyrosine.Approved, Investigational
RamiprilRamipril may increase the hypotensive activities of Metyrosine.Approved
RasagilineRasagiline may increase the hypotensive activities of Metyrosine.Approved
RemifentanilRemifentanil may increase the sedative activities of Metyrosine.Approved
RemikirenRemikiren may increase the hypotensive activities of Metyrosine.Approved
RemoxiprideRemoxipride may increase the sedative activities of Metyrosine.Approved, Withdrawn
RescinnamineRescinnamine may increase the hypotensive activities of Metyrosine.Approved
ReserpineReserpine may increase the sedative activities of Metyrosine.Approved
RilmenidineMetyrosine may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatRiociguat may increase the hypotensive activities of Metyrosine.Approved
RisperidoneRisperidone may increase the sedative activities of Metyrosine.Approved, Investigational
RitanserinRitanserin may increase the sedative activities of Metyrosine.Investigational
RituximabMetyrosine may increase the hypotensive activities of Rituximab.Approved
RomifidineRomifidine may increase the sedative activities of Metyrosine.Vet Approved
RopivacaineRopivacaine may increase the sedative activities of Metyrosine.Approved
S-EthylisothioureaS-Ethylisothiourea may increase the sedative activities of Metyrosine.Experimental
SafrazineSafrazine may increase the hypotensive activities of Metyrosine.Withdrawn
Sage 547Sage 547 may increase the sedative activities of Metyrosine.Investigational
SaprisartanSaprisartan may increase the hypotensive activities of Metyrosine.Experimental
ScopolamineScopolamine may increase the sedative activities of Metyrosine.Approved
SecobarbitalSecobarbital may increase the sedative activities of Metyrosine.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Metyrosine.Approved, Investigational, Vet Approved
SelexipagSelexipag may increase the hypotensive activities of Metyrosine.Approved
SertindoleSertindole may increase the sedative activities of Metyrosine.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Sertraline.Approved
SevofluraneSevoflurane may increase the sedative activities of Metyrosine.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Metyrosine.Approved, Investigational
SitaxentanSitaxentan may increase the hypotensive activities of Metyrosine.Approved, Investigational, Withdrawn
Sodium oxybateSodium oxybate may increase the sedative activities of Metyrosine.Approved
SpiraprilSpirapril may increase the hypotensive activities of Metyrosine.Approved
StiripentolStiripentol may increase the sedative activities of Metyrosine.Approved
SufentanilSufentanil may increase the sedative activities of Metyrosine.Approved, Investigational
SulpirideSulpiride may increase the sedative activities of Metyrosine.Approved
SuvorexantSuvorexant may increase the sedative activities of Metyrosine.Approved
TadalafilTadalafil may increase the antihypertensive activities of Metyrosine.Approved, Investigational
TandospironeTandospirone may increase the sedative activities of Metyrosine.Investigational
TapentadolTapentadol may increase the sedative activities of Metyrosine.Approved
TasimelteonTasimelteon may increase the sedative activities of Metyrosine.Approved
TelmisartanTelmisartan may increase the hypotensive activities of Metyrosine.Approved, Investigational
TemazepamTemazepam may increase the sedative activities of Metyrosine.Approved
TemocaprilTemocapril may increase the hypotensive activities of Metyrosine.Experimental, Investigational
TerlipressinTerlipressin may increase the hypotensive activities of Metyrosine.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Tetrabenazine.Approved
TetracaineTetracaine may increase the sedative activities of Metyrosine.Approved, Vet Approved
TetrodotoxinTetrodotoxin may increase the sedative activities of Metyrosine.Investigational
ThalidomideThalidomide may increase the sedative activities of Metyrosine.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the sedative activities of Metyrosine.Approved, Vet Approved
ThiopentalThiopental may increase the sedative activities of Metyrosine.Approved, Vet Approved
ThioproperazineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Thioproperazine.Approved
ThioridazineThioridazine may increase the sedative activities of Metyrosine.Approved
ThiothixeneThiothixene may increase the sedative activities of Metyrosine.Approved
TiagabineTiagabine may increase the sedative activities of Metyrosine.Approved
TianeptineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Tianeptine.Approved
TiaprideTiapride may increase the sedative activities of Metyrosine.Investigational
TiboloneTibolone may increase the hypotensive activities of Metyrosine.Approved
TicrynafenTicrynafen may increase the hypotensive activities of Metyrosine.Withdrawn
TiletamineTiletamine may increase the sedative activities of Metyrosine.Vet Approved
TimololTimolol may increase the hypotensive activities of Metyrosine.Approved
TizanidineTizanidine may increase the sedative activities of Metyrosine.Approved
TolazolineTolazoline may increase the hypotensive activities of Metyrosine.Approved, Vet Approved
TolcaponeTolcapone may increase the sedative activities of Metyrosine.Approved, Withdrawn
ToloxatoneToloxatone may increase the hypotensive activities of Metyrosine.Approved
TopiramateTopiramate may increase the sedative activities of Metyrosine.Approved
TorasemideTorasemide may increase the hypotensive activities of Metyrosine.Approved
TramadolTramadol may increase the sedative activities of Metyrosine.Approved, Investigational
TrandolaprilTrandolapril may increase the hypotensive activities of Metyrosine.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the sedative activities of Metyrosine.Experimental
TranylcypromineTranylcypromine may increase the sedative activities of Metyrosine.Approved
TravoprostTravoprost may increase the hypotensive activities of Metyrosine.Approved
TrazodoneTrazodone may increase the sedative activities of Metyrosine.Approved, Investigational
TreprostinilTreprostinil may increase the hypotensive activities of Metyrosine.Approved, Investigational
TriazolamTriazolam may increase the sedative activities of Metyrosine.Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Metyrosine.Approved, Vet Approved
TrifluoperazineTrifluoperazine may increase the sedative activities of Metyrosine.Approved
TriflupromazineTriflupromazine may increase the sedative activities of Metyrosine.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Metyrosine.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Metyrosine.Approved
TrimipramineTrimipramine may increase the sedative activities of Metyrosine.Approved
TriprolidineTriprolidine may increase the sedative activities of Metyrosine.Approved
Uc1010Uc1010 may increase the sedative activities of Metyrosine.Investigational
UdenafilUdenafil may increase the antihypertensive activities of Metyrosine.Approved, Investigational
UnoprostoneUnoprostone may increase the hypotensive activities of Metyrosine.Approved
Valproic AcidValproic Acid may increase the sedative activities of Metyrosine.Approved, Investigational
ValsartanValsartan may increase the hypotensive activities of Metyrosine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Metyrosine.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Venlafaxine.Approved
VigabatrinVigabatrin may increase the sedative activities of Metyrosine.Approved
VinpocetineMetyrosine may increase the hypotensive activities of Vinpocetine.Investigational
VortioxetineVortioxetine may increase the sedative activities of Metyrosine.Approved
XylazineXylazine may increase the sedative activities of Metyrosine.Vet Approved
XylometazolineXylometazoline may increase the hypotensive activities of Metyrosine.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Metyrosine.Approved, Vet Approved
ZaleplonZaleplon may increase the sedative activities of Metyrosine.Approved, Illicit, Investigational
ZiconotideZiconotide may increase the sedative activities of Metyrosine.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Zimelidine.Withdrawn
ZiprasidoneZiprasidone may increase the sedative activities of Metyrosine.Approved
ZolazepamZolazepam may increase the sedative activities of Metyrosine.Vet Approved
ZolpidemZolpidem may increase the sedative activities of Metyrosine.Approved
ZonisamideZonisamide may increase the sedative activities of Metyrosine.Approved, Investigational
ZopicloneZopiclone may increase the sedative activities of Metyrosine.Approved
ZotepineZotepine may increase the sedative activities of Metyrosine.Approved
ZuclopenthixolZuclopenthixol may increase the sedative activities of Metyrosine.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

DrugSyn.org

US2868818
General ReferencesNot Available
External Links
ATC CodesC02KB01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9918
Blood Brain Barrier-0.8678
Caco-2 permeable-0.7026
P-glycoprotein substrateSubstrate0.5286
P-glycoprotein inhibitor INon-inhibitor0.9891
P-glycoprotein inhibitor IINon-inhibitor0.9926
Renal organic cation transporterNon-inhibitor0.9278
CYP450 2C9 substrateNon-substrate0.8025
CYP450 2D6 substrateNon-substrate0.7432
CYP450 3A4 substrateNon-substrate0.6887
CYP450 1A2 substrateNon-inhibitor0.9459
CYP450 2C9 inhibitorNon-inhibitor0.951
CYP450 2D6 inhibitorNon-inhibitor0.9574
CYP450 2C19 inhibitorNon-inhibitor0.9116
CYP450 3A4 inhibitorNon-inhibitor0.892
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9735
Ames testNon AMES toxic0.9695
CarcinogenicityNon-carcinogens0.8681
BiodegradationNot ready biodegradable0.7891
Rat acute toxicity2.1516 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9852
hERG inhibition (predictor II)Non-inhibitor0.9728
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Aton pharma inc
Packagers
Dosage forms
FormRouteStrength
CapsuleOral250 mg/1
Prices
Unit descriptionCostUnit
Demser 250 mg capsule19.35USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point312.5 °CPhysProp
water solubilityVery slightly solubleNot Available
logP-1.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.48 mg/mLALOGPS
logP-1.9ALOGPS
logP-1.1ChemAxon
logS-1.9ALOGPS
pKa (Strongest Acidic)2.06ChemAxon
pKa (Strongest Basic)9.93ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area83.55 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity51.81 m3·mol-1ChemAxon
Polarizability19.9 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpropanoic acids. These are compounds with a structure containing a benzene ring conjugated to a propanoic acid.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassPhenylpropanoic acids
Sub ClassNot Available
Direct ParentPhenylpropanoic acids
Alternative Parents
Substituents
  • 3-phenylpropanoic-acid
  • L-alpha-amino acid
  • D-alpha-amino acid
  • Amphetamine or derivatives
  • Alpha-amino acid or derivatives
  • Alpha-amino acid
  • Phenylpropane
  • Aralkylamine
  • Phenol
  • Amino fatty acid
  • Fatty acyl
  • Benzenoid
  • Monocyclic benzene moiety
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Primary aliphatic amine
  • Carbonyl group
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
binder
General Function:
Tyrosine 3-monooxygenase activity
Specific Function:
Plays an important role in the physiology of adrenergic neurons.
Gene Name:
TH
Uniprot ID:
P07101
Molecular Weight:
58599.545 Da
References
  1. Nasrallah HA, Donnelly EF, Bigelow LB, Rivera-Calimlim L, Rogol A, Potkin S, Rauscher FP, Wyatt RJ: Inhibition of dopamine synthesis in chronic schizophrenia. Clinical ineffectiveness of metyrosine. Arch Gen Psychiatry. 1977 Jun;34(6):649-55. [PubMed:17374 ]
  2. Yoshimoto Y, Nakaso K, Nakashima K: L-dopa and dopamine enhance the formation of aggregates under proteasome inhibition in PC12 cells. FEBS Lett. 2005 Feb 14;579(5):1197-202. Epub 2005 Jan 21. [PubMed:15710413 ]
  3. Shore PA, Dorris RL: On a prime role for newly synthesized dopamine in striatal function. Eur J Pharmacol. 1975 Feb;30(2):315-8. [PubMed:1168577 ]
  4. Moore KE, Demarest KT, Johnston CA: Influence of prolactin on dopaminergic neuronal systems in the hypothalamus. Fed Proc. 1980 Sep;39(11):2912-6. [PubMed:7409209 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23